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Cyclooxygenase-2 inhibition decreases primary and
metastatic tumor burden in a murine model of orthotopic
lung adenocarcinoma
Costanzo A. DiPerna, MD,a Robert D. Bart, MD,c Eric M. Sievers, MD,a Yanling Ma, MD,b Vaughn A. Starnes, MD,a and
Ross M. Bremner, MD, PhDc
Objective: To assess cyclooxygenase-2 inhibition on primary tumor and
mediastinal metastases in a murine model of orthotopic lung adenocar-
cinoma.
Methods: Human lung adenocarcinoma cells (CRL5908, female non-
smoker with cyclooxygenase-2 expression by Western blot) were im-
planted under direct visualization through the parietal pleura in the upper
lobe of the left lung (2  106 cells/animal) of SCID mice. Mice were
randomly assigned to 2 groups, either untreated (n  62) or celecoxib-
treated (n 60). Celecoxib, a selective cyclooxygenase-2 antagonist, was
solubilized in the animals’ drink (25 mg/kg per day). Mice were arbi-
trarily killed at 1, 2, 3, and 4 weeks. A blinded observer assessed primary
tumor volume and metastatic disease grossly and histologically.
Results: Gross metastatic lymph nodes were present at 3 weeks in none
of 15 (0%) treated and 12 of 15 (80.0%) untreated animals (P  .0001). Mean
primary tumor volumes at 3 weeks for treated mice were 7.9  10.0 mm3 and for
untreated mice were 533.1 453.6 mm3 (mean SD, P .0001). Gross metastatic
lymph nodes were present at 4 weeks in 3 of 15 (20%) treated and 17 of 17 (100%)
untreated animals (P  .0001). Mean primary tumor volumes at 4 weeks for treated
mice were 37.1  46.2 mm3 and for untreated mice were 809.6  1226.4 mm3
(mean  SD, P  .0001). Mean blood levels of celecoxib in treated mice were
236.8  34.2 ng/mL (mean  SD).
Conclusions: Cyclooxygenase-2 inhibition results in decreased primary and meta-
static tumor burden in a murine model using human lung adenocarcinoma. Cyclo-
oxygenase-2 inhibition has the potential to decrease tumor progression and metas-
tases in patients with lung adenocarcinoma.
Despite timely detection and “curative resection” for early-stagelung cancer, 5-year survival remains at 60%.1 In many survivorsrecurrence will take the form of distant disease, implying thepresence of micrometastases at the time of surgery.2-4 Adjuvantchemotherapy has not dramatically improved overall survival.1This shortcoming stems from chemotherapy protocols developed
without adequate understanding of functional biologic differences between histo-
logically similar lung cancers. A necessity exists to subdivide lung cancers on the
basis of genetic and biochemical, not histologic, differences.3,5 The knowledge that
allows us to categorize lung cancers biologically will give us the insight necessary
to develop more effective targeted therapies.
Cyclooxygenase enzymes convert arachidonic acid to prostaglandins. Cycloox-
ygenase-1 is the constitutive isoform and cyclooxygenase-2 (COX-2) is the induc-
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ible isoform. COX-2 is overexpressed in human adenocar-
cinomas including colon, lung, breast, bladder, pancreas,
and uterus.6 Although its specific role in carcinogenesis is
not defined, the presence of COX-2 is believed to promote
a metastatic phenotype. Non-small cell lung cancer cells
transfected with human COX-2 cDNA demonstrated an
enhanced invasive capacity compared with control cells.7
Recent literature demonstrates a correlation between
COX-2 expression and prognosis, where increased expres-
sion of COX-2 is associated with a poorer prognosis from
lung adenocarcinoma.8,9
An in vitro study using colorectal cancer cells found
etodolac, a COX-2 inhibitor, exerted cytotoxic effects and
suppressed the invasive property of these cancer cells.10
Using mice subjected to injection of a murine colon cancer
cell line overexpressing COX-2, Tomozawa and col-
leagues11 found a significant reduction in metastatic lung
nodules in animals treated with a COX-2 inhibitor. Al-
though the exact mechanisms remain unclear, the inhibition
of COX-2 appears to attenuate, if not prevent, carcinogen-
esis or metastatic tumor progression. The aim of this study
is to assess COX-2 inhibition on primary tumor growth and
mediastinal metastases in a murine model of orthotopic lung
cancer expressing COX-2.
Methods
Cell Culture
Human female lung adenocarcinoma cells expressing COX-2 by
Western blot (CRL5908, female nonsmoker; American Type Cul-
ture Collection, Manassas, Va) were cultured in media (Roswell
Park Memorial Institute [RPMI] medium 1640; 10% fetal bovine
serum [FBS]) until 90% confluent. Cells were trypsinized, washed,
centrifuged, and resuspended to a concentration of 2  106 cells
per 25 L in RPMI 1640 (cell passage 35  3). Cell viability
before and after injections was greater than 94% (trypan blue
stain).
Animal Model
Animal study was approved by the University of Southern Cali-
fornia Institutional Animal Care and Use Committee. All animals
received humane care in compliance with the “Guide for the Care
and Use of Laboratory Animals” published by the National Insti-
tutes of Health.
Six-week-old mice with severe combined immunodeficiency
(SCID bg male mice; Harlan Sprague Dawley, Inc, Indianapolis,
Ind) were housed in polycarbonate cages (5 per cage) in a room lit
for 12 hours each day and maintained at 27°C for 2 days before
injection. Teklad (4%) diet (Harlan Teklad, Madison, Wis) and tap
water were provided ad libitum. Mice were randomly assigned into
2 groups, untreated (n  60) or celecoxib treated (n  62).
Celecoxib, a selective COX-2 antagonist, was solubilized in the
animals’ drink to provide 25 mg/kg of drug per day.12-14 Admin-
istration began 1 day before tumor cell implantation and continued
until the animals were killed. Mice were anesthetized by titrating
isoflurane inhalant. A 1-cm subscapular incision allowed left lung
visualization through intercostal muscles and pleura. Cancer cells
were injected (25 L with 2.0  106 cells; 27-gauge needle) into
the left upper lobe at the fourth intercostal space. The incision was
closed with 4-0 chromic suture and mice were allowed to recover.
Mice were arbitrarily selected and killed at 1, 2, 3, and 4 weeks (n
 30/week with 15 each in treated and untreated, except 4 weeks
untreated  17) after implantation. All treated animals survived
until killed, whereas 2 untreated animals died, 1 at day 24 and 1 at
day 26. Before death, blood samples were obtained for celecoxib
assay (Pharmacia, St Louis, Mo). At necropsy, a blinded observer
assessed the presence of mediastinal lymph nodes and measured
the primary tumor volume. Primary tumors and mediastinal nodes
were snap-frozen in a beaker of 2-isopropanol on Dry Ice
(18°C).
Histology
Frozen sectioning of primary tumors and lymph nodes was per-
formed (4-m sections on polylysine-coated slides). Sections were
sequentially blocked for endogenous peroxidase (3% H2O2 in
methanol) and nonspecific protein binding [1% bovine serum
albumin [BSA] in phosphate-buffered saline soltuion (PBS)]. All
tissue sections, excluding negative controls but including positive
controls (breast adenocarcinoma), were incubated overnight at 4°C
in the presence of COX-2 goat anti-rat polyclonal antisera (Alpha
Diagnostic Intl, San Antonio, Tex). Subsequently, isoform-specific
polyclonal anti-goat antisera (DAKO Corporation, Carpinteria,
Calif) were diluted 1:100 in PBS for all sections. Immunoreactive
complexes were detected using diaminobenzidine (DAB, Sigma
Chemical, St Louis, Mo). Slides were counterstained with aqueous
hematoxylin, mounted in crystal solution (Biomeda, Foster City,
Calif), and coverslipped.
Statistical Methods
The 2-sided Fisher exact test was used to evaluate the statistical
significance of the presence of lymph nodes between treated and
untreated mice. The difference of mean values between treated and
untreated mouse tumor volumes was evaluated by the Mann-
Whitney U test. Two-factor analysis of variance was used to study
the effect of time and study group on tumor volume. SPSS (version
11.0, SPSS Inc, Chicago, Ill) statistical software was used for
statistical testing.
Results
At 1 week, small left lung upper lobe adenocarcinoma
nodules were present in all treated 15/15 (100%) and un-
treated 15/15 (100%) animals. At 2 weeks, all untreated
animals exhibited primary tumor growth with histologic
lymphatic invasion in 15 of 15 (100%). Gross metastatic
lymph nodes were present at 3 weeks in none of 15 (0%)
treated and 12 of 15 (80.0%) untreated animals (P  .0001;
2-sided Fisher exact test; Figure 1). Mean primary tumor
volumes from all 4 weeks are graphed (Figure 2). Mean
primary tumor volumes at 3 weeks for treated mice were 7.9
 10.0 mm3 and for untreated mice were 533.1  453.6
mm3 (mean  SD, P  .0001; Mann-Whitney U test). A
representative gross comparison of treated and untreated
tumors is shown in Figure 3. Gross metastatic lymph nodes
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were present at 4 weeks in 3 of 15 (20%) treated and 17 of
17 (100%) untreated animals (P  .0001; 2-sided Fisher
exact test; Figure 1). Mean primary tumor volumes at 4
weeks for treated mice were 37.1  46.2 mm3 and for
untreated mice were 809.6  1226.4 mm3 (mean  SD, P
 .0001; Mann-Whitney U test). Two-factor analysis of
variance showed no statistically significant difference be-
tween week 3 and week 4 groups (P  .3819), no statisti-
cally significant interaction between week and experiment
group (P  .4788), and a statistically significant difference
between treated and untreated groups (P .0004). A subset
of pathologic specimens were randomly selected and under-
went immunohistochemistry for COX-2 with hematoxylin
counterstain. These specimens stained positive for the pres-
ence of COX-2. Mean blood levels of celecoxib at 3 and 4
weeks were 236.8  34.2 ng/mL (mean  SD). Two of the
Figure 1. Lymph nodes identified on gross examination (percent of mice with mediastinal lymph nodes) are
compared between celecoxib-treated and untreated mice at each respective week. Weeks 3 and 4 were
significant for differences between treated and untreated groups (P < .0001; 2-sided Fisher exact test).
Figure 2. Primary tumor volumes (mean  SD) are compared between celecoxib-treated and untreated mice at
each respective week. Weeks 3 and 4 were significant for differences between treated and untreated groups (P
< .0001; Mann-Whitney U test).
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3 treated animals that developed mediastinal nodal metas-
tases had the lowest blood levels for celecoxib.
Discussion
The persistent inability to improve 5-year survival from
lung cancer combined with an evolving understanding of
cellular biochemistry has provided the motivation and tools
necessary for the development of novel biologic compounds
directed at specific functional characteristics of the tumor.
With improved understanding of signaling pathways and
cellular biochemistry, new compounds can be developed
and evaluated. The most prominent novel agents currently
under study include epidermal growth factor receptor
(EGFR) inhibitors, matrix metalloproteinases, E-cadherin
promoters, and COX-2 inhibitors. Blocking EGFR inhibits
tumor cell proliferation, leading to diminished tumor viru-
lence.15 Inhibition of matrix metalloproteinases leads to
decreased angiogenesis and stabilization of the extracellular
matrix; stopping both processes results in decreased meta-
static potential.16,17 Promotion of E-cadherin results in im-
proved cellular adhesion, leading to a less metastatic phe-
notype.18-20 COX-2 inhibition promotes apoptosis,
decreases angiogenesis, and diminishes metastases in many
human cancers.14,21,22 COX-2 appears to be functionally
related to many proteins including EGFR and E-cadherin.6
Both primary and metastatic disease were deterred by the
COX-2 inhibitor celecoxib in the current study. Human lung
adenocarcinoma tumor growth was found to be significantly
less at 3 weeks of therapy and continued to be less through
the termination of the study at 4 weeks. This was not the
regression of preexisting tumor mass but the prevention of
growth as compared with untreated animals. The evaluation
of metastatic disease was limited to mediastinal lymph node
disease. At 2 weeks, mice in both the treated and untreated
groups had no lymph nodes discernable on gross examina-
tion. As the mice progressed to 3 and 4 weeks after cancer
cell injection, a difference was found between the treated
and untreated groups. The mice treated with celecoxib had
significantly fewer tumor-involved lymph nodes at both
time points.
Blood levels of celecoxib reported in this study are
comparable with those previously published.14,23 These lev-
els correlate well with those attained in clinical use of cele-
coxib.24 An interesting observation is that the mice with the
lowest levels of celecoxib were the individuals in which met-
astatic disease developed. Additional study is needed to define
the strength of this potential correlation of an inverse relation-
ship between celecoxib blood levels and cancer disease.25
The structure of this study initiated celecoxib treatment
as a baseline shortly before injection of cancer cells. The
treated mice developed primary tumor lesions and by 4
weeks 20% of these developed nodal lesions. Given this
finding, it is unclear whether COX-2 inhibition is tumori-
static or tumoricidal. Altering some of the parameters in this
study may allow an improved understanding of COX-2 and
its inhibition. If celecoxib therapy is initiated at an interval
after primary tumor is established, suppression of further
tumor growth versus tumor regression may shed light on
this question. The current study is limited to a 4-week
interval. Subsequent studies extending the period of obser-
vation to 8 or 12 weeks or longer may aid in understanding
the length of time tumors are responsive to COX-2 inhibi-
tors. Another limitation is the fact that the cell line was
chosen specifically because it expressed COX-2; use of
adenocarcinoma cells that do not express COX-2 may yield
different results.
COX-2 inhibitors are one of many potential novel che-
motherapeutic agents. Although the role of COX-2 and
pharmacologic inhibition in normal cells is understood, our
current understanding does not pinpoint the specific mech-
Figure 3. Three-week necropsy specimens consisting of left upper lung lobe, heart, and mediastinum with arrows
indicating tumor in celecoxib-treated (A) and untreated (B) mice.
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anism by which COX-2 inhibitors work in cancer. This
study, along with others, provides evidence that COX-2
inhibitors may be effective in the treatment of lung cancer.
Further studies are needed to determine the long-term effi-
cacy of COX-2 inhibition, whether this provides permanent
suppression, disease regression, and duration of therapy.
These studies need to be performed in both animal models
and humans. Ultimately, COX-2 inhibitors could be an
adjuvant to standard chemotherapeutics, leading to in-
creased survival for patients with lung cancer.
We thank Mr Robert Salazar and Dr Yangsun Jin for their
expert technical assistance. Additionally, we thank Linda S. Chan,
PhD, for her review of the statistical analysis.
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